Pharmacophore Elucidation and Molecular Docking Studies on 5-Phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid Derivatives as COX-2 Inhibitors by Lindner, Marc et al.
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
Pharmacophore Elucidation and  
Molecular Docking Studies on 5-Phenyl- 
1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid 
Derivatives as COX-2 Inhibitors 
Marc LINDNER 
1, Wolfgang SIPPL 
1, Awwad A. RADWAN * 
2,3 
1  Department of Pharmaceutical Chemistry, Martin-Luther-Universität Halle-Wittenberg, 06120 Halle, 
Germany. 
2 Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut-71527, 
Egypt. 
3 Current address: Pharmaceutical Technology and Manufacturing Center, College of Pharmacy, King Saud 
University Al Ryiadh, Kingdom of Saudi Arabia, P. O. Box 2457, Riyadh, 11451, Kingdom of Saudi Arabia. 
* Corresponding author. E-mail: dhna_2001@hotmail.com (A. A. Radwan) 
Sci Pharm. 2010; 78: 195–214        doi:10.3797/scipharm.0912-19 
Published:   March 19
th  2010   Received:    December  20
th 2009 
Accepted:   March 18
th 2010 
This article is available from: http://dx.doi.org/10.3797/scipharm.0912-19 
© Lindner et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
A set of 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid derivatives 
(16–32) showing anti-inflammatory activity was analyzed using a three-
dimensional qualitative structure-selectivity relationship (3D QSSR) method. 
The CatalystHipHop approach was used to generate a pharmacophore model 
for cyclooxygenase-2 (COX-2) inhibitors based on a training set of 15 active 
inhibitors (1–15). The degree of fitting of the test set compounds (16–32) to the 
generated hypothetical model revealed a qualitative measure of the more or 
less selective COX-2 inhibition of these compounds. The results indicate that 
most derivatives (16, 18, 20–25, and 30–32) are able to effectively satisfy the 
proposed pharmacophore geometry using energy accessible conformers (Econf 
< 20 kcal/mol). In addition, the triazole derivatives (16–32) were docked into 
COX-1 and COX-2 X-ray structures, using the program GOLD. Based on the 
docking results it is suggested that several of these novel triazole derivatives 
are active COX inhibitors with a significant preference for COX-2. In principle, 
this work presents an interesting, comprehensive approach to theoretically 
predict the mode of action of compounds that showed anti-inflammatory activity 
in an in vivo model. 196  M. Lindner, W. Sippl, and A. A. Radwan:   
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Introduction 
In early 1990, isolation of cyclooxygenase isoforms and other findings had led to an initial 
hypothesis that cyclooxygenase-1 (COX-1) is responsible for the physiological function of 
prostaglandins (PGs), whereas COX-2 produces the “bad” PGs during inflammation 
processes. There are two central tenets of the hypothesis, firstly the PGs that mediate 
inflammation are produced solely via COX-2 and secondly PGs that are important in 
gastrointestinal and renal function are produced solely via COX-1. In the context of this 
hypothesis, the toxicity of NSAIDs in the gastrointestinal and renal systems is related to 
their lack of selectivity with respect to inhibition of COX-1 and COX-2 [1]. 
  The major differences between the two iso-enzymes involve their dissimilarity in 
regulation and expression. COX-1 is almost detected in all cell types, although the level of 
expression varies among cell types. It is supposed to be the “Housekeeping Gene” which 
is essential for cytoprotection properties in stomach, haemostasis, platelets aggregation as 
well as renal sodium and water balance. In contrast, COX-2 is almost undetectable under 
normal physiological conditions, unless inflammatory mediators induce it [2].
 The structural 
differences between COX-1 and COX-2 are due to two amino acid residues. Replacement 
of Ile523 in COX-1 by a relatively smaller Val in COX-2 is the most important difference 
between the two subtypes. This modification in the COX-2 enzyme allows access to an 
additional side pocket, which is a pre-requisite for COX-2 selectivity. A further important 
difference between the two enzymes is the exchange of His513 of COX-1 by the 
corresponding Arg499 in the COX-2 enzyme [3, 4]. Within the last few years several series 
of highly potent and selective COX-2 inhibitors have been reported [5–14]. 
Palomer et al. [15] described the construction of a pharmacophore using four known 
selective COX-2 inhibitors – celecoxib, rofecoxib, valdecoxib, and SC-558 – and 
considering the X-ray structure of COX-2 complexed with the selective inhibitor SC-558. 
The reported pharmacophore model shows a hydrogen bond acceptor, an aromatic ring 
(ring A) and an additional aromatic ring (ring B). Moreover, an excluded volume, which 
corresponds to Val523 was used for this structure-based pharmacophore [15]. 
5-Phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid derivatives (16–32) were recently 
synthesized in our group and tested in an animal model showing good anti-inflammatory 
activity [16]. We therefore considered it a worthy research endeavor to study the selective 
COX-2 inhibitory capability of these compounds by pharmacophore analysis and docking 
studies. 
The Catalyst program [17] is generally used to analyze how ligands interact with a receptor 
by evaluating chemical features common to a set of active ligands (HipHop) [18] or by 
elucidating the correlation between activity and chemical binding features (HypoGen) [19]. 
One application of the Catalyst program is the generation of hypotheses that attempt to 
correlate the biological activity observed for a series of compounds to their chemical 
structures. The hypotheses are represented by chemical features that describe a series of 
compounds (e.g. hydrogen bonding acceptors (HBAs), positive and negative ionizable   Molecular Modeling of 1,2,4-Triazoles as COX-2 Inhibitors  197 
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groups, etc). The hypotheses generated may be used to estimate the biological activity for 
potential drugs, allowing to rank potential synthetic priorities. In addition, the hypotheses 
generated may be used as three-dimensional queries to search databases of proprietary 
and/or commercially available compounds. In this study, we used the Catalyst program to 
establish a COX-2 pharmacophore by analyzing a variety of selective COX-2 inhibitors. 
The generated pharmacophore model was validated using a test set of triazole 
compounds (16–32) recently reported as anti-inflammatory agents. The COX-2 selectivity 
of these compounds was predicted using the Catalyst model. Complementary docking 
studies were carried out on the same set of triazole derivatives. The docking results 
suggested that these triazole derivatives are able to interact with the COX active site and 
are therefore suggested to be COX inhibitors with a clear preference for COX-2.  
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Fig. 1.  Structures of selective COX-2 inhibitors used in the Catalyst training set. 
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Results and Discussion 
Common Feature-Based Pharmacophore Models 
Fig. 1 shows the structures of training set compounds (1–15) that are reported as selective 
COX-2 inhibitors [3, 20–30]. On the assumption that the most active compounds bind in a 
similar fashion at the enzyme’s active site, we employed the Catalyst/HipHop approach to 
evaluate the common features required for binding and the hypothetical geometries 
adopted by these ligands in their most active forms. Thus, these compounds were 
submitted for pharmacophore model generation based on common chemical features. 
Diverse conformation within 20 kcal/mol energy range were generated and submitted to 
the Catalyst/HipHop program. In the model generation methodology, the highest weighting 
was given to the most “selective” compound(s) in the training set (compounds 6, 8, 14, 
15). Moreover, an excluded volume nearby the “selectivity filter” Val523 (which is known to 
be important for COX-1/2 selectivity) was set as sterically forbidden region in this 
structure-based pharmacophore. The crystallographic information was used to position an 
excluded volume in the pharmacophore accounting for the space limits imposed by this 
excluded volume [15].
  The top-ranked chemical feature-based pharmacophore model 
identified in this study is shown in Fig. 2. This pharmacophore model contains three 
chemical features: two aromatic ring, R, (gray) and one hydrogen bond acceptor, HBA, 
(green). Fig. 3 shows as an example the alignment of the hypothesis model with 
compound 14 (celecoxib) of the training set. 
 
Fig. 2.  The top-ranked chemical feature-based pharmacophore model developed using 
the HipHop module in Catalyst. The pharmacophore includes two aromatic rings 
(gray) and one hydrogen bond acceptor feature (cyan). Distances are given in 
Angstrom.   Molecular Modeling of 1,2,4-Triazoles as COX-2 Inhibitors  199 
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Fig. 3.  Compound 14 (celecoxib, training set) mapped to the HipHop pharmacophore. 
In silico prediction of selective COX-2 inhibiting activity and qualitative 3D-SSR 
analysis 
This strategy intends to investigate the selective COX-2 inhibitory activity of a test set of 5-
phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid derivatives (Fig. 4) [16]. As a 
readout, the HipHop program expresses the degree of mapping of a given compound to a 
generated hypothetical model in terms of fit values. The higher the fit value, the higher the 
expected activity against COX-2 enzyme. The Best fit method was used to map the 
chemical functions of each compound in the test set to the obtained hypothetical model 
and selects the most suitable alignment among its conformations. The fit values of the test 
set compounds obtained as well as their conformational energies are listed in Table 1. Fig. 
5 and 6 show the alignment of the hypothesis model with compounds 25 and 32, 
respectively, of the test set. 
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Fig. 5.  Compound 25 mapped to the HipHop pharmacophore.  
 
Fig. 6.  Compound 32 mapped to the HipHop pharmacophore.  202  M. Lindner, W. Sippl, and A. A. Radwan:   
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Examination of the inhibitor binding site. 
A variety of COX-2-ligand crystal structures have been solved over the last years 
[3,  20,  21]. These X-ray structures provide important information about the relevant 
interaction possibilities at the COX-2 binding pocket. The COX-2 pocket is deeply buried 
within the protein at the end of a hydrophobic channel. The entrance of this channel is 
located nearby the membrane binding domain [22]. Structure–activity relationship data for 
first generation COX-2 inhibitors such as celecoxib and rofecoxib have shown that a 
SO2NH2, or a SO2Me substituent at the para-position of one of the aryl rings is a 
requirement for optimum COX-2 selectivity and potency. The X-ray structure 1CX2 with 
the co-crystallized celecoxib derivative SC-558 [23] is used to show the relevant protein-
inhibitor interactions (Fig. 7a and 8a). The N-1 phenyl ring possessing the sulfonamide 
group is oriented in the vicinity of the COX-2 secondary pocket (nearby Ile517, Phe518). 
The sulfonamide accepts a hydrogen bond from the backbone NH of Phe518 (Fig. 7a). A 
second hydrogen bond is observed with His90. The para-bromophenyl-ring is oriented 
towards a hydrophobic pocket surrounded by the aromatic residues Trp387, Tyr385 and 
Phe518. The central pyrazole shows a hydrogen bond to Tyr355. The CF3-substituent is 
oriented toward the mouth of the COX-2 binding site, where it is located nearby Leu359 
and Arg120 [24].  
COX-1 has also been crystallized with a variety of inhibitors (Table 1) [22, 25–30]. As an 
example, Fig. 7b shows the COX-1 X-ray structure with the co-crystallized flurbiprofen. 
The carboxylate group is hydrogen bonded to Tyr355 and Arg120, while the aromatic rings 
are located in the hydrophobic area at the apex of the binding site. The terminal aromatic 
ring is stabilized by Leu352, Tyr385, and Trp387 (Fig. 7b).  
Tab. 1.  Fit values of the investigated compounds 16–32 (test set) to the hypothetical 
model. 
Compound 
number 
No. of 
conformers  Fit value  Energy of best 
fitting conformer 
16   18  2.88   4.10 
17   23  2.12   0.06 
18   21  2.72   0.09 
19 106  2.57    0.001 
20   83  2.87   0.00 
21   26  2.87   4.09 
22   15  2.88   4.01 
23   49  2.90   1.06 
24   40  2.88   0.20 
25   11  2.90   0.10 
26   74  2.61  10.47 
27   37  2.56   3.09 
28   44  2.58   4.10 
29   52  2.63   3.27 
30   11  2.87   4.70 
31   36  2.89   5.08 
32   24  2.90   8.02 
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Tab. 2.  COX protein-ligand X-ray structures used for the docking study. The rmsd 
values (heavy atoms) between experimentally observed and docked ligand 
structure (top rank) are indicated. 
Pdb 
code  Co-crystallized ligand  Subtype  Ref.  RMSD 
(top rank)
1CQE Flurbiprofen  COX1  [22]   0.43 
1Q4G 2-(1,1'-Biphenyl-4-yl)propanoic acid   COX1  [27]    0.32 
1DIY Arachadonic  acid  COX1  [26]    3.65 
1EQG Ibuprofen  COX1  [30]   0.23 
1EQH Flurbiprofen  COX1  [30]   0.23 
1FE2 Eicosa-8,11,14-trienoic acid  COX1  [29]  11.37 
1HT5 Flurbiprofen  methylester  COX1  [30]    1.03 
1HT8 (3-Chloro-4-propoxyphenyl)acetic acid   COX1  [30]    1.29 
1IGX 5,8,11,14,17-Eicosapentaenoic acid   COX1  [25]    2.49 
1IGZ Linoleic  acid  COX1  [25]    1.72 
1PGE Iodosuprofen  COX1 [28]    0.55 
1PGF Iodoindomethacin  COX1  [28]    0.76 
1PGG Iodoindomethacin  COX1  [28]   1.04 
1CVU Arachadonic  acid  COX2  [25]   1.22 
1CX2 SC-558  COX2  [3]    1.01 
1DDX Prostaglandine  G2 COX2  [21]    4.63 
1PXX Diclofenac  COX2  [20]    5.83 
3PGH Flurbiprofen  COX2  [3]    0.40 
4COX Indomethacin  COX2  [3]    0,78 
6COX SC-558  COX2  [3]    0.40 
 
Docking results 
In a first step we tested whether the docking program GOLD was able to reproduce the 
experimentally observed interaction mode of the 20 co-crystallized ligands (Table  2). 
Different docking settings and scoring functions were tested for the experimentally derived 
20 COX-ligand complexes. The co-crystallized ligands can be classified based on their 
chemical structures: fatty acids, monocyclic inhibitors, bicyclic, or annealed tricyclic 
inhibitors. Docking with Goldscore and Chemscore showed comparable results and 
accuracy, whereas XScore [31] performed slightly worse (data not shown). Goldscore 
reproduced about 80–90% of the co-crystallized inhibitors correctly (rmsd within 2 Å, see 
Table 3). Most of the inhibitors were correctly predicted by GOLD, whereas the docking of 
the flexible fatty acids was less successful (see Tables 2 and 3). From the group of the 
inhibitors only diclofenac was not correctly docked. In a second step we tested whether 
using docking constraints (protein-ligand hydrogen bonds, hydrophobic constraints) could 
improve the docking accuracy. Using a combination of hydrophobic and hydrogen bond 
constraints extracted from the superimposed X-ray structures (Fig. 7a and 7b), a slight 
improvement in accuracy and correctness was observed (Tables 2 and 3). 204  M. Lindner, W. Sippl, and A. A. Radwan:   
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Fig. 7a.  COX-2 docking constraints: For comparison the co-crystallized celecoxib 
derivative SC-558 (from 1CX2.pdb) is shown (coloured dark gray). The orange 
circles indicate the applied hydrophobic constraints whereas the hydrogen bond 
constraint is shown in magenta. 
 
Fig. 7b.  COX-1 docking constraints: For comparison the co-crystallized inhibitor 
Flurbiprofen (from 1CQE.pdb) is shown (coloured dark gray). The orange circles 
indicate the applied hydrophobic constraints whereas the hydrogen bond 
constraints are indicated by dashed lines.    Molecular Modeling of 1,2,4-Triazoles as COX-2 Inhibitors  205 
Sci Pharm. 2010; 78: 195–214. 
 
Fig. 7c.  Comparison of the COX-2/SC-558 complex obtained from the crystal structure 
and the Catalyst COX-2 pharmacophore. The violet spheres indicate the two 
aromatic features whereas the hydrogen bond acceptor is shown in orange. The 
excluded volume (green) of the pharmacophore coincides with Val523 of 
COX-2. 
The 17 synthesized compounds were subsequently docked into the COX-1 and COX-2 
binding pocket using the same docking parameters as used for the validation set. The 
triazole derivatives show comparable interactions at COX-2 as the co-crystallized SC-558. 
As examples the docking solutions obtained for compounds 18 and 27 at COX-2 are 
shown in Fig. 8a and 8b in comparison with SC-558. The docked compounds fit well into 
the binding pocket and show hydrogen bonds with Tyr355, His90, Arg513, Gln192, 
Leu352, and the backbone NH of Ile517 and Phe518. The polar C3 substituent of the 
triazole ring fits into the COX-2 secondary pocket showing a similar interaction as the 
sulfonamide group of SC-558. One of the aromatic rings adopts the position of the central 
pyrazole ring of SC-558 whereas the second aromatic ring can be superimposed with the 
bromophenyl ring of SC-558. 
In a next step we compared the binding mode obtained by docking with the Catalyst 
pharmacophore model. The same features as observed in the COX-2 pharmacophore 
were detected in the docking poses. The superimposition of the COX-2 pharmacophore 
with the COX-2/SC-558 complex is shown in Fig. 7c. The two hydrophobic features match 
the two aromatic rings of SC-558 used as docking constraints (Fig. 7a and 7c), whereas 
the hydrogen bond acceptor is located in close direction to Arg499. The excluded volume 
in the pharmacophore matches the position of Val523, which is known to be responsible 
for the COX-2 selectivity of the coxib derivatives.  206  M. Lindner, W. Sippl, and A. A. Radwan:   
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Tab. 3.  GOLD/GoldScore docking results for the 20 co-crystallized ligands. Twelve of 
the co-crystallized inhibitors can be reproduced within 2 Å (retrieval rate: 86%) 
and thirteen by using constraints (retrieval rate: 92%). 
Retrieval rate without constraints
0
2
4
6
8
10
12
14
RMSD<2Å RMSD>2Å,
RMSD<4Å
RMSD>4Å
non fatty acids
fatty acids
 
Retrieval rate with constraints
0
2
4
6
8
10
12
14
RMSD<2Å RMSD>2Å,
RMSD<4Å
RMSD>4Å
non fatty acids
fatty acids
 
 
In a next step we compared the binding mode obtained by docking with the Catalyst 
pharmacophore model. The same features as observed in the COX-2 pharmacophore 
were detected in the docking poses. The superimposition of the COX-2 pharmacophore 
with the COX-2/SC-558 complex is shown in Fig. 7c. The two hydrophobic features match 
the two aromatic rings of SC-558 used as docking constraints (Fig. 7a and 7c), whereas 
the hydrogen bond acceptor is located in close direction to Arg499. The excluded volume 
in the pharmacophore matches the position of Val523, which is known to be responsible 
for the COX-2 selectivity of the coxib derivatives.    Molecular Modeling of 1,2,4-Triazoles as COX-2 Inhibitors  207 
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Fig. 8a.  COX-2: superimposition of the co-crystallized Celecoxib derivative SC-558 
(from 1CX2.pdb, coloured cyan) and the docked compound 27 (coloured 
magenta). Hydrogen bonds are displayed in magenta.  
 
Fig. 8b.  COX-2: superimposition of the co-crystallized celecoxib derivative SC-558 (from 
1CX2.pdb, coloured cyan) and the docked compound 18 (coloured orange). 
Hydrogen bonds are displayed in magenta.  208  M. Lindner, W. Sippl, and A. A. Radwan:   
Sci Pharm. 2010; 78: 195–214. 
 
Fig. 9a.  COX-1: superimposition of the co-crystallized flurbiprofen (from 1EQH.pdb, 
coloured cyan) and the docked compound 27 (coloured magenta). Hydrogen 
bonds are displayed in magenta.  
 
Fig. 9b.  COX-1: superimposition of the co-crystallized flurbiprofen (from 1EQH.pdb, 
coloured cyan) and the docked compound 18 (coloured orange). Hydrogen 
bonds are displayed in magenta.   Molecular Modeling of 1,2,4-Triazoles as COX-2 Inhibitors  209 
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Docking into the COX-1 binding pocket showed that the triazole derivatives show all a 
similar interaction mode. As examples, the obtained docking solutions for compounds 18 
and 27 are shown in comparison with the co-crystallized inhibitor flurbiprofen in Fig. 9a, 
9b. The central triazole ring adopts the same position as the central aromatic ring of 
flurbiprofen. The two aromatic rings of the ligands are oriented towards the hydrophobic 
pocket nearby Leu352. The polar substituent attached to the triazole is hydrogen bonded 
to Tyr355 and Arg120 as the carboxylate of the COX-1 inhibitors. Due to the fact that no 
tricyclic inhibitor has been co-crystallized with COX-1 yet, the interaction mode of the 
synthesized derivatives is more speculative. Comparison of docking scores that we 
obtained for the co-crystallized inhibitors, the training- and test set molecules yielded a 
preference of the triazole derivatives for COX-2. Therefore, based on our docking results it 
is suggested that the synthesized triazole derivatives are active COX inhibitors with a clear 
preference for COX-2.  
We had no access to COX in vitro assay data and thus it was not able to carry out a 
quantitative structure activity relationship. However, several compounds of the training set 
were recently tested in animal models for their anti-inflammatory activity and their gastric 
ulceration effects [16]. Compounds 16 and 25 showed no effect in the ulceration test, while 
compounds 24 and 32 caused gastrointestinal lesions in a dose-dependent manner. It is 
known that gastric ulceration effects of COX inhibitors are mainly the results of blocking 
the COX-1 mediated pathway. The derived docking scores (Table 4) for the COX-1 
inhibitors are in qualitative agreement with the effects measured in the gastric ulceration 
model. Compound 24 was the top-scored COX-1 inhibitor among all docked compounds. 
On the other hand, compound 25, the most active one in the anti-inflammatory model, was 
found to be the top-scored inhibitor for COX-2.  
Tab. 4.  Calculated docking scores for COX-1 and COX-2. 
Inhibitor  GoldScore COX-1  GoldScore COX-2 
16 44.7  49.1 
24 58.1  51.8 
25 44.6  61.7 
32 53.5  45.3 
 
Methods 
Common Feature-Based Pharmacophore Models. Selective COX-2 Inhibitors 
The study was performed using the Catalyst 4.7 software [17] on a 195 MHz MIPS R10K 
Octane (IRIX64). All compounds were constructed using the 2D/3D sketcher of the 
Catalyst software. By use of the conformational poling approach [32], a conformational 
model was generated for each compound within a 20 kcal/mol range above the calculated 
energy minimum (BEST search method in Catalyst). The numbers of calculated 
conformations range from 11 to 106 for the different compounds. 
Feature-based 3D pharmacophore alignments of COX-2 inhibitors were performed using 
the Catalyst/HipHop program [33, 34]. This was carried out in a three-step procedure: [35] 
(a) a conformational model for each molecule in the training set of 15 selective COX-2 210  M. Lindner, W. Sippl, and A. A. Radwan:   
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inhibitors was generated; (b) each conformer was examined for the presence of chemical 
features; (c) a three-dimensional configuration of chemical features common to the input 
molecules was determined. Catalyst provides a dictionary of chemical features found to be 
important in drug-enzyme/receptor interactions. These are hydrogen bond donors, 
hydrogen bond acceptors, hydrophobic groups, and positive and negative ionizable 
groups. For the pharmacophore modeling, common features selected for the run were 
aromatic ring (R) and hydrogen bond acceptor (HBA) functions. 
In silico prediction of COX-2 inhibiting activity and qualitative 3D-SSR analysis 
A set of 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid derivatives (16–32) that 
have been reported as anti-inflammatory agents, were allowed to fit to the generated 
hypothetical model of selective COX-2 inhibitors. The crystallographic information was 
used to position an excluded volume in the pharmacophore accounting for the space limits 
imposed by this excluded volume [15]. Best conformational analysis was performed for 
each compound using a threshold of 250 conformers per molecule and a maximum value 
of 20 kcal/mol for conformer energy. Subsequently, the conformers of each synthesized 
compound were allowed to fit to the generated hypothetical model utilizing the best fit 
method. The obtained fit value for each molecule is a measure of how many and how well 
its functional features fit to the features of the pharmacophore. 
Docking study 
All calculations were performed on a Pentium IV 1.8 GHz based Linux cluster. The 
molecular structures of the ligands were generated using Sybyl 7.1 [36]. The ligand 
structures were energy minimized using the MMFF94s force field and the conjugate 
gradient method, until the default derivative convergence criterion of 0.05 kcal/(mol Å) was 
reached. All compounds were generated in the protonation state assuming physiological 
conditions. 
The coordinates of 13 Cyclooxygenase-1 (COX-1) and 7 Cyclooxygenase-2 (COX-2) X-ray 
structures were taken from the Protein Data Bank [37]. COX-1 and COX-2 are monomers 
in solution, and therefore only one chain from the available X-ray structures was 
considered for docking. To validate the GOLD docking we used the 20 X-ray structures as 
validation set (Table 1). The 20 co-crystallized ligands were docked into their original 
protein structures after removing all co-crystallized ligands and solvent molecules. For the 
docking of the developed inhibitors we selected the X-ray structures of 1EQH and 1CX2 as 
representatives for COX-1 and COX-2, respectively. 
Docking of all ligands was carried out using the program GOLD 3.0 [38] (Cambridge 
Crystallographic Data Centre, CCDC). Docking was performed with default settings to 
obtain a population of possible conformations and orientations for the inhibitors at the 
binding site. A 10 Å sphere around the centre of the binding pocket was defined as binding 
pocket for the docking. All torsion angles in each compound were allowed to rotate freely. 
Goldscore, Chemscore and, Xscore [31] were tested as fitness functions. The resulting 
solutions were clustered on the basis of the heavy atom rmsd values (1 Å). For each 
molecule, 10 individual docking runs were performed. The docking poses for each ligand 
were stored in a MOE database and further processed using in-house MOE-SVL-scripts 
(Chemical Computing Group, CCG) [39].   Molecular Modeling of 1,2,4-Triazoles as COX-2 Inhibitors  211 
Sci Pharm. 2010; 78: 195–214. 
Conclusions 
In this work we have developed a pharmacophore hypothesis and carried out docking 
studies on 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid derivatives as COX-2 
inhibitors. These studies resulted in a reliable COX-2 pharmacophore model and allowed 
us to shed light on the binding features of these derivatives to COX-1 and COX-2 which 
showed a clear preference for COX-2. The derived pharmacophore model were found to 
be in agreement with the structural features at the COX-2 binding site. These findings 
could be exploited for future ligand design in order to obtain novel triazole derivatives as 
selective COX-2 inhibitor. 
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